M2 macrophage activation in recurrent acute pancreatitis: an explorative analysis of a randomized controlled trial.

Scand J GastroenterolJul 3, 2026 (epub)
Clinical ResearchGastroenterology

Rasmus Hagn-Meincke, Mathias E Cook, Jens B Frøkjær et al.

✦ AI-curated · Sources linked

In 30 seconds

This exploratory analysis of a multicenter, randomized controlled trial evaluated M2 macrophage activation in 56 patients with recurrent acute pancreatitis (RAP) treated with naldemedine or placebo for 12 months. Although naldemedine showed a numerical reduction in RAP frequency (hazard ratio 0.49), it did not significantly alter M2 macrophage biomarkers sCD163 or sCD206 compared to placebo.

Key findings

  • Naldemedine showed a numerical reduction in RAP frequency with a hazard ratio of 0.49.
  • No significant changes in sCD163 (-0.07 mg/L, p = 0.652) or sCD206 (0.01 mg/L, p = 0.299) were observed.
  • sCD163 levels correlated with RAP attack frequency (rho = 0.348, p = 0.009) and pain flares (rho = 0.318, p = 0.017).

Why it matters

Understanding the role of M2 macrophage activation in RAP could inform future therapeutic strategies. The correlation between sCD163 levels and disease activity suggests potential biomarkers for monitoring disease progression.

Source

PubMed · PMID 42396887

Published in Scand J Gastroenterol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.